Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 5 versus TRAVASOL 5 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 5 versus TRAVASOL 5 5 W O ELECTROLYTES.
AMINOSYN II 5% vs TRAVASOL 5.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 5% provides essential and non-essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair. It supports metabolic processes in patients unable to maintain adequate nutrition enterally.
TRAVASOL 5.5% W/O ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and nitrogen balance in patients unable to tolerate enteral nutrition. It serves as a substrate for gluconeogenesis and other metabolic processes.
Intravenous infusion via central line, initial rate 50 mL/hour, increase by 25 mL/hour every 24 hours to goal rate of 1-2 mL/kg/hour (maximum 125 mL/hour). Total daily dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 30-40 mL/kg/day).
Intravenous infusion, 500 mL to 2000 mL per day as a component of total parenteral nutrition (TPN), providing 5.5% amino acids. Rate should be individualized based on metabolic requirements and tolerance.
None Documented
None Documented
Not applicable as a single entity; individual amino acids have variable half-lives (e.g., 10-30 min for most), reflecting rapid distribution and metabolism. Clinical context: continuous infusion maintains steady state.
Not applicable as a fixed drug; the clearance of infused amino acids follows saturable kinetics with a functional half-life of approximately 30-60 minutes for free amino acids in plasma, reflecting rapid uptake and metabolism. Clinical context: continuous infusion maintains steady-state levels.
Renal elimination of amino acids is minimal under normal conditions; excess amino acids are metabolized, and nitrogen is excreted as urea (renal, ~80-90%) and ammonia. Biliary/fecal excretion negligible.
Primarily renal excretion of amino acids and metabolites; approximately 70-80% of infused amino acids are converted to urea and excreted in urine, with the remainder undergoing metabolism or incorporation into body proteins. Biliary/fecal excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution